33 completed, 6 active not recruiting, 6 recruiting, 3 terminated. 53 Phase 2, 19 Phase 1, 2 Phase 3.
Follow Metal Metabolism, Inborn Errors: new trials by email Literature Review of Metal Metabolism, Inborn Errors trials Research Report on Metal Metabolism, Inborn Errors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) PM577a - Wilson Disease, Wilson's Disease | Phase 1 / Phase 2 | Recruiting | Prime Medicine, Inc. | 42 | 2026-09-01 | 2026-10-01 |
| NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease Droxidopa Oral Product, Placebo Control - Menkes Disease | Phase 1 / Phase 2 | Recruiting | Stephen G. Kaler | 6 | 2026-08-10 | 2026-10-05 |
| Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) Setmelanotide - Pseudohypoparathyroidism Type 1a, Obesity | Phase 2 | Enrolling by invitation | Massachusetts General Hospital | 1 | 2026-07-21 | 2026-07-23 |
| Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease LY-M003 Injection - Wilson's Disease | Phase 1 / Phase 2 | Not yet recruiting | Lingyi Biotech Co., Ltd. | 18 | 2026-06-15 | 2026-07-02 |
| A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis BBI-001, Placebo - Hereditary Hemochromatosis | Phase 1 / Phase 2 | Recruiting | Bond Biosciences | 34 | 2026-05-04 | 2026-05-13 |
| Evaluation of the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD) GC310 - Wilson Disease | Phase 1 / Phase 2 | Recruiting | GeneCradle Inc | 15 | 2026-02-20 | 2026-11-17 |
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis Vamifeport, Placebo - Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Phase 2 | Active not recruiting | CSL Behring | 84 | 2026-01-22 | 2026-10-21 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1 ALE1, Placebo - Hypophosphatasia (HPP) | Phase 1 / Phase 2 | Recruiting | Alesta Therapeutics | 120 | 2025-09-30 | 2026-08-03 |
| Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride New TETA 4HCl Formulation, Standard of Care - Wilson's Disease | Phase 2 | Completed | Orphalan | 10 | 2025-07-15 | 2026-04-06 |
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia KK8123 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 39 | 2024-10-09 | 2026-11-06 |
| Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia Ilofotase Alfa, 0.8 mg/kg, Ilofotase Alfa, 3.2 mg/kg - Hypophosphatasia | Phase 1 / Phase 2 | Completed | AM-Pharma | 12 | 2023-05-15 | 2025-02-27 |
| A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease UX701, Standard of Care (SOC) - Wilson Disease | Phase 1 / Phase 2 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 82 | 2021-09-27 | 2026-09-25 |
| A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease VTX-801 - Wilson's Disease | Phase 1 / Phase 2 | Active not recruiting | Vivet Therapeutics SAS | 4 | 2021-09-03 | 2026-01-30 |
| NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome Droxidopa, Placebo - Menkes Disease, Occipital Horn Syndrome | Phase 1 / Phase 2 | Completed | Stephen G. Kaler, MD | 3 | 2021-07-12 | 2026-04-13 |
| Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Bis-Choline Tetrathiomolybdate - Wilson Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 31 | 2020-12-02 | 2024-10-18 |
| Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 ALXN1840 - Wilson Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 9 | 2020-09-07 | 2024-06-24 |
| Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old Theophylline, Placebo - Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy | Phase 2 | Active not recruiting | Vanderbilt University Medical Center | 34 | 2020-07-13 | 2026-04-29 |
| Theophylline for Treatment of Pseudohypoparathyroidism Theophylline ER - Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a | Phase 2 | Enrolling by invitation | Jaclyn Tamaroff | 34 | 2020-05-22 | 2026-09-02 |
| PTG-300 in Subjects With Hereditary Hemochromatosis PTG-300 - Hereditary Hemochromatosis | Phase 2 | Completed | Protagonist Therapeutics, Inc. | 16 | 2020-03-19 | 2025-08-20 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
Showing 20 of 53. Sign in to see all of them.
Hemochromatosis (14) · Hypophosphatasia (12) · Hepatolenticular Degeneration (9) · Familial Hypophosphatemic Rickets (8) · Iron Overload (8) · Bone Diseases (7) · Osteomalacia (7) · Rickets (7) · Pseudohypoparathyroidism (6) · Menkes Kinky Hair Syndrome (3) · Thalassemia (3) · Autonomic Nervous System Diseases (2) · Myelodysplastic Syndromes (2) · Anemia (1) · Anemia, Diamond-Blackfan (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (53) · Genetic Diseases, Inborn (53) · Metabolism, Inborn Errors (53) · Nutritional and Metabolic Diseases (53) · Metabolic Diseases (52) · Musculoskeletal Diseases (22) · Bone Diseases, Metabolic (21) · Calcium Metabolism Disorders (21) · Nutrition Disorders (16) · Avitaminosis (15) · Deficiency Diseases (15) · Malnutrition (15) · Vitamin D Deficiency (15) · Bone Diseases (14)
asfotase alfa (9) · burosumab (6) · Deferasirox (4) · Deferoxamine (3) · Phlebotomy (3) · Theophylline (3) · Droxidopa (2) · Standard of Care (2) · Bumetanide (1) · Deferiprone (1) · Growth Hormone (1) · Interleukin 1 Receptor Antagonist Protein (1) · Long Interspersed Nucleotide Elements (1) · Saline Solution (1) · copper histidine (1)
Alexion Pharmaceuticals, Inc. (11) · Kyowa Kirin Co., Ltd. (3) · Kyowa Kirin, Inc. (3) · Novartis Pharmaceuticals (3) · Vanderbilt University Medical Center (3) · Rennes University Hospital (2) · Ultragenyx Pharmaceutical Inc (2) · AM-Pharma (1) · Alesta Therapeutics (1) · Bicetre Hospital (1) · Bond Biosciences (1) · CSL Behring (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GeneCradle Inc (1) · Haukeland University Hospital (1)
United States (32) · United Kingdom (16) · Canada (13) · France (10) · Germany (10) · Spain (7) · Italy (6) · Australia (5) · New Zealand (5) · Austria (3) · China (3) · Denmark (3) · Russia (3) · Switzerland (3) · United Arab Emirates (3)
Jaclyn Tamaroff, MD (3) · Amy Zhang, PhD (2) · Eugene S. Swenson, MD, PhD (2) · Anna Davidsson (1) · Ashley H Shoemaker, MD, MSCI (1) · Chaohui Yu, PhD (1) · Curtis Scribner, MD (1) · Doreen Fialho, MD, PhD (1) · Eugene Swenson, MD, PhD (1) · Francesco Equitani, M.D. (1) · Keiichi Ozono (1)
PMID 26529632, PMID 32417537, PMID 32762706, PMID 25919461, PMID 27699270, PMID 32721016, PMID 39151033, PMID 15923132, PMID 16278898, PMID 17482283, PMID 17959863, PMID 18256395, PMID 18752978, PMID 19194885, PMID 20497190, PMID 20652413, PMID 22134099, PMID 22397652, PMID 2265118, PMID 24385534, PMID 24916507, PMID 25281031, PMID 25345697, PMID 26073451, PMID 28436937, PMID 28822957, PMID 28988934, PMID 29791829, PMID 30558909, PMID 30638856, PMID 30811537, PMID 30969260, PMID 32987199, PMID 33822385, PMID 34636899, PMID 36072994, PMID 37863080, PMID 41378916, PMID 42016919, PMID 42044650, PMID 7842019, PMID 8295415, PMID 8419622, PMID 8526465, PMID 8812725, PMID 9633879
2025 (2), 2014 (1), 2016 (1), 2019 (1)